The pill version hit up to 12.2% mean weight loss at the top dose in phase II, versus 1.3% on placebo. Viking also has a maintenance study and an amylin drug in early testing.
Recap by typeshit. Full story at Yahoo Finance.
A new GLP-1 described as stronger than current options is being tested in trials, and researchers lay out what people should understand about it.
A SURPASS-4 analysis at ASN Kidney Week 2026 found rapid kidney decline in 5% on tirzepatide versus 13% on insulin glargine, with the biggest gains in high protein groups.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
Researchers used AI to identify fungal peptides that taste salty or boost saltiness, aimed at cutting sodium in food. A food science find rather than a drug story.
MassLive reports the nationwide recall tied to Mounjaro and Zepbound's active ingredient was upgraded, and explains how to check whether your supply is affected.
Visits climbed from about five a month to over 217 in a little more than a year. NSW Health warns that a polished label says nothing about what a vial contains.
Loading…